OTCMKTS:IMUCD

ImmunoCellular Therapeutics Stock Forecast, Price & News

$0.51

0.00 (0.00 %)

(As of 05/17/2021 12:00 AM ET)

Add

Compare

Today's Range

$0.47

▼

$0.51

50-Day Range

$0.31

▼

$0.58

52-Week Range

$0.16

▼

$0.51

Volume10,042 shs

Average Volume6,605 shs

Market Capitalization$2.14 million

P/E RatioN/A

Dividend YieldN/A

Beta1.63

30 days | 90 days | 365 days | Advanced Chart

Receive IMUCD News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoCellular Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About ImmunoCellular Therapeutics

ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 30, 2006 and is headquartered in Calabasas, CA.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:IMUCD

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.imuc.com

Phone(818) 264-2300

Employees3

Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Miscellaneous

Outstanding Shares4,190,000

Market Cap$2.14 million

Next Earnings DateN/A

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

Medical Sector

1973rd out of 2,032 stocks

Pharmaceutical Preparations Industry

758th out of 768 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for ImmunoCellular Therapeutics.

0.0 Community Rank

Outperform Votes
ImmunoCellular Therapeutics has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ImmunoCellular Therapeutics has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about ImmunoCellular Therapeutics and other stocks. Vote “Outperform” if you believe IMUCD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMUCD will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ImmunoCellular Therapeutics does not currently pay a dividend.
Dividend Growth
ImmunoCellular Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ImmunoCellular Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.28% of the stock of ImmunoCellular Therapeutics is held by insiders.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

ImmunoCellular Therapeutics (OTCMKTS:IMUCD) Frequently Asked Questions

What stocks does MarketBeat like better than ImmunoCellular Therapeutics?

Wall Street analysts have given ImmunoCellular Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ImmunoCellular Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are ImmunoCellular Therapeutics' key executives?

ImmunoCellular Therapeutics' management team includes the following people:

Mr. Gary S. Titus CPA, Independent Chairman & Corp. Sec. (Age 60, Pay $63k)
Mr. Sanford J. Hillsberg, Co-Founder (Age 71)
Dr. John S. Yu, Founder & Director (Age 56)

Who are some of ImmunoCellular Therapeutics' key competitors?

Some companies that are related to ImmunoCellular Therapeutics include Acura Pharmaceuticals (ACUR), Peak Pharmaceuticals (PKPH), BetterLife Pharma (BETRF), GlobeImmune (GBIM), Kaya (KAYS), Parnell Pharmaceuticals (PARNF), Nexien BioPharma (NXEN), Helix BioMedix (HXBM), Cotinga Pharmaceuticals (COTQF), Intellipharmaceutics International (IPCIF), BriaCell Therapeutics (BCTXF), FutureWorld (FWDG), Wellness Center USA (WCUI), Pivotal Therapeutics (PVTTF) and RespireRx Pharmaceuticals (RSPI).
View all of IMUCD's competitors.

What is ImmunoCellular Therapeutics' stock symbol?

ImmunoCellular Therapeutics trades on the OTCMKTS under the ticker symbol "IMUCD."

How do I buy shares of ImmunoCellular Therapeutics?

Shares of IMUCD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoCellular Therapeutics' stock price today?

One share of IMUCD stock can currently be purchased for approximately $0.51.

How much money does ImmunoCellular Therapeutics make?

ImmunoCellular Therapeutics has a market capitalization of $2.14 million.

How many employees does ImmunoCellular Therapeutics have?

ImmunoCellular Therapeutics employs 3 workers across the globe.

What is ImmunoCellular Therapeutics' official website?

The official website for ImmunoCellular Therapeutics is www.imuc.com.

How can I contact ImmunoCellular Therapeutics?

The company can be reached via phone at (818) 264-2300.

This page was last updated on 5/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

ImmunoCellular Therapeutics Stock Forecast, Price & News

Adding

Adding

Adding ImmunoCellular Therapeutics, Ltd.

About ImmunoCellular Therapeutics

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

0.0 Community Rank

Outperform Votes

Underperform Votes

0.0 Dividend Strength

Dividend Yield

Dividend Growth